Methods: Portuguese retrospective study, comprising 567 patients diagnosed with HMC in 12 hospitals. There were evaluated clinical, genetic, electrocardiographic, echocardiographic and magnetic resonance parameters. Mean follow-up duration was 8.0±6.1 years, no difference in length between male (M) and female (F) was found. The clinical endpoints of interest were dysrhythmic events, stroke, cardiovascular mortality and all cause mortality.
Results: The main characteristics by gender, at presentation, are listed in table 1.
At initial evaluation, F patients were older and more symptomatic than M patients. No gender differences were observed in genetic, electrocardiographic and echocardiographic parameters. Regarding CMR parameters, late enhancement was more prevalent in M patients (51% vs 67%, p=0.04).
Although F were more symptomatic, there were no differences in progression to chronic heart failure, medical treatment, implantation of ICD, dysrhythmic events, stroke and all cause mortality. HCM-related mortality and risk of sudden death were similar in men and women. After adjusting for age, NYHA functional class and late enhancement, no differences were observed between genders.
Conclusion: As previously reported on HCM, women are older, more symptomatic and have worse prognosis. But unlike the other studies, in our population, the female gender was not associated with a worse prognosis.